The primary-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and excessive response charges for sufferers with blastic plasmacytoid dendritic cell neoplasm (BPDCN), in accordance with information from a Section I/II research led by researchers from The College of Texas MD Anderson Most cancers Middle.
These outcomes counsel that PVEK ought to be thought-about a possible new commonplace remedy choice for sufferers with BPDCN, a uncommon, aggressive blood most cancers that includes the pores and skin, bone marrow and lymph nodes.
Findings from the CADENZA research had been offered on the 2025 American Society of Scientific Oncology (ASCO) Annual Assembly by Naveen Pemmaraju, who led the trial along with Naval Daver.
As a frontline remedy in 33 newly recognized sufferers with BPDCN, researchers noticed an general response price of 85%, together with an entire response price of 70% with a median general survival of 16.6 months.
“Sufferers with BPDCN are in want of improved frontline therapies to deal with their illness, so we’re very excited to see this trial going extraordinarily nicely by way of security and efficacy,” Pemmaraju stated. “The responses we have now noticed make PVEK a powerful candidate as a standard-of-care remedy.”
The present standard-of-care remedy for sufferers with BPDCN is tagraxofusp-erzs, which targets CD123 discovered at excessive ranges on sure most cancers cells, together with BPDCN. MD Anderson researchers helped advance tagraxofusp-erzs towards Meals and Drug Administration approval in 2018.
PVEK represents a subsequent era of CD123-targeted remedy. As an ADC, it really works by delivering a drug on to most cancers cells by focusing on CD123 on the floor of BPDCN cells, leading to dying of the most cancers cells.
The worldwide multi-center trial enrolled a complete of 84 grownup sufferers with CD123-positive BPDCN. Of those sufferers, 33 sufferers had been newly recognized, and 51 sufferers had relapsed or refractory BPDCN with one, two or three prior traces of remedy. Contributors acquired the remedy intravenously on day considered one of a 21-day cycle in an outpatient setting.
The commonest negative effects included peripheral edema, which was reversible and located to be manageable.
Given the outcomes of this trial, there’s potential for investigating mixture therapies of CD123-targeted agent PVEK with different remedies lively in BPDCN in future scientific trials, Pemmaraju defined.
The scientific trial was funded by AbbVie. Pemmaraju has served on the advisory board and as a guide for AbbVie. Daver has acquired analysis help and has served on the advisory board and as a guide for AbbVie.
Extra data:
Summary: conferences.asco.org/abstracts-presentations/244202
Quotation:
Antibody-drug conjugate reveals promising security and response charges for sufferers with uncommon blood most cancers (2025, June 2)
retrieved 2 June 2025
from https://medicalxpress.com/information/2025-06-antibody-drug-conjugate-safety-response.html
This doc is topic to copyright. Aside from any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.
